44 SKIN CARE
makeup remover to reveal the naked truth. A better solution is to fight the problem with its sophisticated
at its roots. Slimexir®
active ingredients directly fights the cause of dark circles and puffiness, the result of fat bulging. For most of us, starting the day with coffee or tea is part of our daily mantra. Xanthines such as caffeine serve as mild stimulants increasing alertness in the central nervous system and warding off sleepiness. These molecules have been found to act as nonselective adenosine receptor agonists1 and as competitive nonselective phosphodiesterase inhibitors2
leading to the
activation of lipolysis. Consequently, with the idea of perking up the tissue and triggering fat decomposition, Rahn has, in X-Melt® (INCI: Xanthine), combined different xanthines in the best possible manner to achieve the optimal synergistic effect, outperforming the effect of caffeine alone. Furthermore, artichoke extract (INCI: Cynara Scolymus Leaf Extract) supports X-Melt’s lipolysis effect and stimulates the circulation and drainage,3
successfully removing the
products of fat breakdown. Sagging skin caused by volume reduction is effectively prevented by levan (INCI: Fructan). Its exceptional cosmetic properties firm and strengthen the skin surface, resulting in irregularities appearing less often.4
-10 D29 5 10
n Placebo n Active 4%
0
-5 * ** D84
Figure 2: Application of an emulsion with 4% active significantly reduces skin roughness. The arithmetical mean deviation of the roughness profile (Ra) after 29 and 84 days of treatment was significantly improved (1.3% and 5.3%) in comparison to the initial state and against placebo. Placebo treatment did not have any positive effects. The statistical values in blue relate to the comparison of active with the placebo, whereas the black values relate to the comparison with the initial condition. Wilcoxon signed-rank test.
informed consent at the beginning of the study.
Applying
Slimexir improves the appearance of the skin tremendously. It acts on all three levels, namely: fat decomposition, lymphatic drainage and skin firmness.
Material and methods The in vivo study has been performed in accordance with the principles of good laboratory practice (GLP), good clinical practice (GCP), and in compliance with the quality assurance system requirements. The study was in accordance with the World Medical Association’s Declaration of Helsinki. All study participants signed a written
3 2 1 0
-1 -2 -3
* ** *
In a double-blind, placebo-controlled study 40 female subjects (20 per treatment group), between the ages of 35 and 65, with healthy, Caucasian skin and ageing signs, dark circles and eye bags were tested. The volunteers applied either placebo or verum emulsions containing 0 % or 4 % active twice daily for 84 days.
Primos was used to obtain 3D images of the skin topography, measuring eye bag volume and skin smoothness. Changes in the brightness and colour of the skin directly below the eye were determined using a Minolta Chromameter CR 400 as per the L*a*b colour system. An increase in the L* measurement value represents brighter skin. A decrease in the a* measurement value reduces skin reddening and an increase in the b* measurement value reduces blueness. Standardised photographic images obtained
n Placebo n Active 4%
2 0
-2 -4 -6 -8
Mean + SEM n=21;
* D29 D84
Figure 3: Application of an emulsion with 4% active has a significant lightening effect on the eye area. The brightness of the skin (L* value) was measured by conventional chroma meter measurement. The effect was significant over baseline and placebo. The statistical values in blue relate to the comparison of active with the placebo, whereas the black values relate to the comparison with the initial condition. Wilcoxon signed-rank test.
PERSONAL CARE EUROPE
* = p<0.05 ** = p<0.01
-10 -12 -14
* ** * D29 D84
Figure 4: Application of an emulsion with 4% active significantly reduces skin redness. The a* value measurement revealed a significant reduction in skin redness after 29 and 84 days of treatment. Redness was reduced by 8.7% after 29 days and 7.3% after 84 days, respectively. The effect was significant over baseline and placebo. The statistical values in blue relate to the comparison of active with the placebo, whereas the black values relate to the comparison with the initial condition. Wilcoxon signed-rank test.
November 2018
Mean + SEM n=21;
* = p<0.05 ** = p<0.01
with normal, cross polarised and UV lamp of both hemi-faces and the front are obtained before, during and after the treatment (D0, D29 and D84) with the VISIA-CR system (Canfield, US), in order to quantify the evolution of the anti-ageing and brightening effect.
Results
Eye bag volume / skin roughness The instrumental data (fringe projection) showed that application of verum emulsion with 4% active decreased eye bag volume significant over baseline by 6% after 29 days and by over 11% after 84 days on average. While the active produced a significant effect after 28 and 84 days, placebo did not show any effect at all. After 84 days, verum was significantly better than placebo (Fig 1). Furthermore, skin roughness improved remarkably. The arithmetical mean deviation of the roughness profile (Ra) was significantly
n Placebo n Active 4%
**
Mean + SEM n=20;
* = p<0.05 ** = p<0.01
Relative to initial condition (%)
Relative to initial condition (%)
Relative to initial condition (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104
